title: [Efficacy of deep brain stimulation in our patients with Parkinson's disease].
abstract: OBJECTIVE
  In advanced Parkinson's disease, medically refractory motor fluctuation or medically resistant tremor considerably affects quality of life. However, these symptoms can be mostly successfully treated by deep brain stimulation. We analyzed the efficacy of bilateral subthalamic stimulation in our patients with Parkinson's disease.
  
  
  METHODS
  We assessed the clinical data of ten patients who have been treated in the Department of Neurology, Semmelweis University and have been operated in the National Institute of Neurosciences between 2008 and 2011. The Hoehn-Yahr scale score, the Unified Parkinson's Disease Rating Scale score and the Parkinson's Disease Questionnaire 39, as well as the dose of antiparkinson medication were documented prior to and one year after surgery.
  
  
  RESULTS
  Patient condition improved according to the Hoehn-Yahr scale, approximately by two stages. The dose of antiparkinson medication could be reduced by 63.4% (p = 0.005) post operation. Unified Parkinson's Disease Rating Scale scores decreased by 70.9% (p = 0.005). 12 hours after medication withdrawal, execution of daily activity improved by 57.1% (p < 0.01) and motor functions developed by 79.1% (p < 0.01). Duration of dyskinesias decreased by 62.5% (p = 0.018), duration of akinesia diminished by 87.5% (p = 0.005). Quality of life rose by 41.6% (p < 0.01). Neuropsychological tests detected improvement in verbal memory.
  
  
  CONCLUSIONS
  With deep brain stimulation, the dosage of antiparkinson medication could be significantly reduced, with considerable improvements in motor function and quality of life. Although the number of patients is still low, good results have been established by careful patient selection, precise neurosurgical procedure and by appropriate programming and patient care.
authors.affiliation: Semmelweis Egyetem, Neurológiai Klinika, Budapest. tamas.gertrud@med.semmelweis-univ.hu
authors.forename: Gertrúd
authors.initials: G
authors.lastname: Tamás
authors.forename: Annamária
authors.initials: A
authors.lastname: Takáts
authors.forename: Péter
authors.initials: P
authors.lastname: Radics
authors.forename: Ildikó
authors.initials: I
authors.lastname: Rózsa
authors.forename: Eva
authors.initials: E
authors.lastname: Csibri
authors.forename: Gábor
authors.initials: G
authors.lastname: Rudas
authors.forename: Péter
authors.initials: P
authors.lastname: Golopencza
authors.forename: László
authors.initials: L
authors.lastname: Entz
authors.forename: Dániel
authors.initials: D
authors.lastname: Fabó
authors.forename: Loránd
authors.initials: L
authors.lastname: Eross
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D046690:Deep Brain Stimulation / Q000379:methods; D004567:Electrodes, Implanted; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D011597:Psychomotor Performance; D011788:Quality of Life; D020531:Subthalamic Nucleus / Q000503:physiopathology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents